Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
Authors
Keywords
-
Journal
NEUROUROLOGY AND URODYNAMICS
Volume 33, Issue 1, Pages 17-30
Publisher
Wiley
Online
2013-10-14
DOI
10.1002/nau.22505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist
- (2013) Jennifer Lee et al. CLINICAL DRUG INVESTIGATION
- 401 The incidence of antimuscarinic-associated side effects in overactive bladder (OAB) patients treated with mirabegron: Results of a pooled analysis of 3 randomised phase 3 trials
- (2013) V. Nitti et al. EUROPEAN UROLOGY SUPPLEMENTS
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
- (2013) V. W. Nitti et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A phase II dose-ranging study of mirabegron in patients with overactive bladder
- (2013) Christopher R. Chapple et al. INTERNATIONAL UROGYNECOLOGY JOURNAL
- Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers
- (2013) Gary D. Novack et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- 1958 COMBINATION TREATMENT WITH MIRABEGRON AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER (OAB) - EFFICACY RESULTS FROM A PHASE 2 STUDY (SYMPHONY)
- (2013) Paul Abrams et al. JOURNAL OF UROLOGY
- Urodynamics and Safety of the β3-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
- (2013) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome
- (2013) Yasuhiko Igawa et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
- (2012) Adrian Wagg et al. BJU INTERNATIONAL
- Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
- (2012) M Malik et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder
- (2012) Eliot H. Ohlstein et al. EUROPEAN UROLOGY
- Mirabegron as a New Class of Oral Drug for Overactive Bladder Syndrome: Many Positive Perspectives, Some Concerns
- (2012) Giacomo Novara et al. EUROPEAN UROLOGY
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
- (2012) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
- (2012) Vik Khullar et al. EUROPEAN UROLOGY
- 684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial
- (2012) V. Khullar et al. EUROPEAN UROLOGY SUPPLEMENTS
- OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat
- (2012) Itaru Maruyama et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- In vitroinhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist
- (2012) Shin Takusagawa et al. XENOBIOTICA
- Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist
- (2012) Shin Takusagawa et al. XENOBIOTICA
- Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder
- (2012) Sherilyn M Notte et al. BMC Urology
- Pharmacological Effect of TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, on Mammalian Detrusor Strips
- (2011) Sayoko Kanie et al. UROLOGY
- Patient-reported reasons for discontinuing overactive bladder medication
- (2009) Joshua S. Benner et al. BJU INTERNATIONAL
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis
- (2008) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Catecholamines Relax Detrusor through 2-Adrenoceptors in Mouse and 3-Adrenoceptors in Man
- (2008) M. Wuest et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium
- (2008) Atsushi Otsuka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now